Chinese pharma claims first Alzheimer's drug approval since ...

China’s drugs regulator has conditionally approved Shanghai Green Valley Pharmaceuticals’ Oligomannate to improve cognitive function in mild to moderate Alzheimer’s disease, the first novel

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

Roche swoops on Dicerna’s gene-silencing hepatitis B drug

Astellas cuts $795m deal with Pandion for type 1 diabetes dr...

Iveric rockets on mid-stage trial of Zimura in dry AMD